Embecta Reports Q2 Earnings Miss and Cuts Fiscal 2026 Guidance
Embecta reported a disappointing second-quarter performance with consolidated revenue falling by about 14.4% year-over-year to $222 million, driven primarily by weakness in its U.S. pen needle business. The company also cut fiscal 2026 revenue guidance and adjusted operating margin and EPS expectations.
Topics: acquisition_strategy financial_results guidance_cut revenue_decline